Proqr Therapeutics Eo 04 Stock Operating Margin

0PQ Stock  EUR 3.40  0.01  0.29%   
PROQR THERAPEUTICS EO 04 fundamentals help investors to digest information that contributes to PROQR THERAPEUTICS's financial success or failures. It also enables traders to predict the movement of PROQR Stock. The fundamental analysis module provides a way to measure PROQR THERAPEUTICS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PROQR THERAPEUTICS stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

PROQR THERAPEUTICS EO 04 Company Operating Margin Analysis

PROQR THERAPEUTICS's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

 = 

Operating Income

Revenue

X

100

More About Operating Margin | All Equity Analysis

Current PROQR THERAPEUTICS Operating Margin

    
  (16.95) %  
Most of PROQR THERAPEUTICS's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PROQR THERAPEUTICS EO 04 is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Competition

Based on the recorded statements, PROQR THERAPEUTICS EO 04 has an Operating Margin of -16.9469%. This is 51.69% lower than that of the Healthcare sector and 84.88% lower than that of the Biotechnology industry. The operating margin for all Germany stocks is notably higher than that of the company.

PROQR Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PROQR THERAPEUTICS's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PROQR THERAPEUTICS could also be used in its relative valuation, which is a method of valuing PROQR THERAPEUTICS by comparing valuation metrics of similar companies.
PROQR THERAPEUTICS is currently under evaluation in operating margin category among its peers.

PROQR Fundamentals

About PROQR THERAPEUTICS Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze PROQR THERAPEUTICS EO 04's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PROQR THERAPEUTICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PROQR THERAPEUTICS EO 04 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in PROQR Stock

PROQR THERAPEUTICS financial ratios help investors to determine whether PROQR Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PROQR with respect to the benefits of owning PROQR THERAPEUTICS security.